What Is Alkermes plc (ALKS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Alkermes plc at its current price of $51.87. The composite intrinsic value is estimated at $34.91 (-32.7% average return), with 9 models flagging overvaluation risk. Model dispersion is worth noting: Markov DDM targets $115.37 (+122.4%), versus EPV at $0.72 (-98.6%). This +221.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ALKS?
13 of 13 models are currently active for ALKS. Of these, 3 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates ALKS's intrinsic value at $19.58, implying -62.3% downside from the current price. See which stocks rank higher →
How Does ALKS Rank in Drug Manufacturers - Specialty & Generic?
Among 13 Drug Manufacturers - Specialty & Generic stocks, ALKS ranks #2 by Quality of Company score. CirclFi's QOC score of 8.4/10 evaluates 32 fundamental signals. A score of 8.4 places ALKS in the top tier.
As a biopharma enterprise, Alkermes plc operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ALKS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ALKS a Value Trap?
CirclFi's Value Trap algorithm assigns ALKS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Alkermes plc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Alkermes plc's fundamental quality profile registers 8.4/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +221.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ALKS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ALKS's 13 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad